Condition: Hepatocellular Carcinoma Non-resectable · Sponsor: Second Affiliated Hospital of Guangzhou Medical University
This study is conducted to evaluate the efficacy and safety of lenvatinib plus SIRT (LEN+SIRT) compared with lenvatinib (LEN) alone for patients with hepatocellular carcinoma (HCC) refractory to transarterial chemoembolization (TACE).
This description comes directly from the study's public registry record.
Mingyue Cai, Dr. · +86-20-34156205 · cai020@yeah.net
Mingyue Cai, Dr. · +86-20-34156205 · zhksh010@163.com
Always discuss trial participation with your own doctor first.
| The Second Affiliated Hospital of Guangzhou Medical University | Guangzhou, Guangdong, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06904196